LYEL

Business Context and Reporting Period

Company: Lyell Immunopharma, Inc. (LYEL)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: Lyell is a clinical-stage cell therapy company focused on developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors. The company's lead program, IMPT-314, is a dual-targeting CD19/CD20 CAR T-cell candidate for aggressive large B-cell lymphoma. In October 2024, Lyell acquired ImmPACT Bio USA Inc., the developer of IMPT-314, to accelerate its pipeline.

Key Financial Metrics

Note: The company has no debt outstanding. Revenue is negligible as the company has no approved products for sale.

Material Changes vs. Prior Period

• Acquisition of ImmPACT: In October 2024, Lyell acquired ImmPACT for approximately $93.7 million in total consideration (cash and stock). This resulted in a one-time $87.2 million expense for acquired in-process research and development (IPR&D) related to IMPT-314.
• Asset Impairment: Due to a sustained decline in stock price and reprioritization of programs, the company recorded a $51.3 million impairment charge on long-lived assets (lease right-of-use assets and leasehold improvements).
• Net Loss Increase: Net loss increased by approximately $108.4 million year-over-year, driven primarily by the IPR&D expense and asset impairment, partially offset by lower personnel costs.
• Operating Expense Reductions: Despite the acquisition-related charges, core Research and Development expenses decreased by $11.3 million and General and Administrative expenses decreased by $14.9 million, reflecting workforce reductions and cost management.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Cash Runway: Management believes existing cash, cash equivalents, and marketable securities ($383.5 million as of Dec 31, 2024) are sufficient to fund operations into 2027.
• 2025 Cash Burn: Net cash use for 2025 is expected to be between $175 million and $185 million.
• Clinical Milestones: The company expects to initiate a pivotal trial for IMPT-314 in the 3rd line+ setting in mid-2025 and a pivotal trial in the 2nd line setting by early 2026.

Key Risks and Contingencies:

• Nasdaq Delisting Risk: The company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00 per share) in January 2025. It must regain compliance within 180 days or face delisting; a reverse stock split is a potential remedy.
• Capital Requirements: The company has never generated product revenue and expects to incur substantial losses for the foreseeable future. Additional capital will be required to complete clinical development and commercialization.
• Integration Risk: Success depends on the effective integration of ImmPACT, including the technology transfer of IMPT-314 manufacturing to Lyell's facility.
• Regulatory Uncertainty: As a clinical-stage company, success is dependent on regulatory approvals which are uncertain and costly.

Investor Verification Checklist

• Stock Price Compliance: Monitor the company's ability to regain compliance with Nasdaq's $1.00 minimum bid price requirement to avoid delisting.
• Cash Burn Rate: Verify the accuracy of the projected $175-$185 million cash burn for 2025 against actual quarterly results.
• IMPT-314 Clinical Data: Review upcoming data presentations (mid-2025) from the Phase 1/2 trial to assess the efficacy and safety profile supporting the planned pivotal trials.
• Manufacturing Transfer: Confirm the progress of transferring IMPT-314 manufacturing from the acquired Los Angeles facility to Lyell's LyFE Manufacturing Center in Bothell, Washington.
• Contingent Consideration: Track the fair value of the $7.6 million contingent consideration liability related to the ImmPACT acquisition, which fluctuates with stock price and milestone probability.